Barclays analyst Gena Wang raised the firm’s price target on Seagen (SGEN) to $228 from $145 and keeps an Equal Weight rating on the shares following the takeover agreement with Pfizer (PFE). The analyst does not see major issues with Federal Trade Commission approval despite some overlapping indications, saying most of the therapies are distinctive in large cancer types that are crowded with many competitors.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN:
- Seagen (NASDAQ:SGEN) Stock Gained 54% YTD. Can Its Momentum Continue?
- Seagen downgraded to Market Perform from Outperform at JMP Securities
- Seagen downgraded to Market Perform from Outperform at BMO Capital
- Needham downgrades Seagen, says competing bid unlikely
- Seagen downgraded to Hold from Buy at Needham
